Examining the Relationship between Quality of Life and Baseline Hemoglobin Level in Lung Cancer with Chemotherapy Treatment Using EORTC QLQ-LC13
Main Article Content
Abstract
Background: The effect of lung cancer and its various treatments on the overall well-being can be substantial. This study seeks to examine the correlation between quality of life and baseline hemoglobin (Hb) levels in lung cancer patients who are receiving chemotherapy.
Method: This study involved 30 patients with non-small cell lung cancer (NSCLC) who underwent platinum-based chemotherapy. Baseline Hb level were collected from medical records. The patients' quality of life was assessed using interviews utilizing the EORTC QLQ-LC13 questionnaire.
Result: Baseline Hb levels and pain relief after medication score was positively correlated (r=0.559, p=0.001). Baseline Hb levels and difficulty swallowing score was negatively correlated (r=-0.386, p=0.035). Determined cut-off point for the total score was 303.5. However, the correlation between Hb levels and overall quality of life was insignificant (r=-0.096, p=0.615).
Conclusion: According to the quality of life indicators in the questionnaire, there is a notable association between lower baseline Hb levels and reduced effectiveness of pain relief medication, as well as an increase in difficulty swallowing. However, the underlying cause for this correlation is unclear. On the other hand, the correlation between baseline Hb levels and the overall scores of quality of life in the questionnaire was not found to be significant.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Translational Lung Cancer Research. 2018 Jun;7(3):220–33.
II. Barta JA, Powell CA, Wisnivesky JP. Global Epidemiology of Lung Cancer. Annals of Global Health. 2019;85(1):8.
III. Prapa P, Papathanasiou IV, Bakalis V, Malli F, Papagiannis D, Fradelos EC. Quality of Life and Psychological Distress of Lung Cancer Patients Undergoing Chemotherapy. World J Oncol. 2021 May 14;12(2–3):61–6.
IV. Pizzoli SFM, Renzi C, Arnaboldi P, Russell-Edu W, Pravettoni G. From life-threatening to chronic disease: Is this the case of cancers? A systematic review. Monacis L, editor. Cogent Psychology. 2019 Jan 1;6(1):1577593.
V. Gluszak C, de Vries-Brilland M, Seegers V, Baroin C, Kieffer H, Delva R, et al. Impact of Iron-Deficiency Management on Quality of Life in Patients with Cancer: A Prospective Cohort Study (CAMARA Study). The Oncologist. 2022 Apr 5;27(4):328–33.
VI. Abdel-Razeq H, Hashem H. Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia. Critical Reviews in Oncology/Hematology. 2020 Jan 1;145:102837.
VII. Nooreldeen R, Bach H. Current and Future Development in Lung Cancer Diagnosis. Int J Mol Sci. 2021 Aug 12;22(16):8661.
VIII. Balboni TA, Hui KKP, Kamal AH. Supportive Care in Lung Cancer: Improving Value in the Era of Modern Therapies. American Society of Clinical Oncology Educational Book. 2018 May 23;(38):716–25.
IX. Barca-Hernando M, Muñoz-Martin AJ, Rios-Herranz E, Garcia-Escobar I, Beato C, Font C, et al. Case-control analysis of the impact of anemia on quality of life in patients with cancer: A Qca study analysis. Cancers. 2021 Jun 1;13(11):2517.
X. Goel A, Bakshi SS, Soni N, Chhavi N. Iron deficiency anemia and Plummer–Vinson syndrome: current insights. J Blood Med. 2017 Oct 19;8:175–84.
XI. Joshi MV, Pohujani SM, Mehta BC, Acharya VN, Kshirsasgar NA. Effect of iron deficiency anaemia and its treatment on single dose phenytoin bioavailability. Eur J Clin Pharmacol [Internet]. 1993 Nov [cited 2023 May 19];45(4). Available from: http://link.springer.com/10.1007/BF00265961
XII. Cochrane A, Woods S, Dunne S, Gallagher P. Unmet supportive care needs associated with quality of life for people with lung cancer: A systematic review of the evidence 2007–2020. European Journal of Cancer Care. 2022 Jan 1;31(1):e13525.
XIII. Coon CD, Schlichting M, Zhang X. Interpreting Within-Patient Changes on the EORTC QLQ-C30 and EORTC QLQ-LC13. Patient. 2022 Nov 1;15(6):691–702.
XIV. Madeddu C, Gramignano G, Astara G, Demontis R, Sanna E, Atzeni V, et al. Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach. Frontiers in Physiology [Internet]. 2018 [cited 2023 Mar 8];9. Available from: https://www.frontiersin.org/articles/10.3389/fphys.2018.01294
XV. Anand S, Burkenroad A, Glaspy J. Workup of anemia in cancer. Clinical Advances in Hematology & Oncology. 2020 Oct;18(10):640–6.
XVI. Macciò A, Gramignano G, Madeddu C. A Multitargeted Treatment Approach for Anemia and Cachexia in Metastatic Castration-Resistant Prostate Cancer. Journal of Pain and Symptom Management. 2015 Aug;50(2):e1–4.
XVII. Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of Incidence, Prevalence, Survival, and Baseline Treatment in Patients With Non–Small Cell Lung Cancer in the US. JAMA Oncol. 2021 Dec;7(12):1–9.
XVIII. Menga M, Sjattar E, Irwan A. ANALYSIS OF FACTORS AFFECTING FATIGUE IN CANCER PATIENTS WITH CHEMOTHERAPY : LITERATURE REVIEW. Jurnal Ilmiah Perawat Manado. 2020;
XIX. Busti F, Marchi G, Ugolini S, Castagna A, Girelli D. Anemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy. Pharmaceuticals (Basel). 2018 Sep 30;11(4):94.
XX. Beckles MA, Spiro SG, Colice GL, Rudd RM. Baseline evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes. Chest. 2003 Jan;123(1 Suppl):97S-104S.
XXI. Yuliandra Y, Nasif H, Ermayanti S, Sulistyowati L, Juwita DA. Hematologic Toxicities of Chemotherapy in Lung Cancer Patients: A Retrospective Study in Dr. M. Djamil Hospital Padang, Indonesia. Indonesian Journal of Clinical Pharmacy. 2019 Jun 28;8(2):129–40.
XXII. Palasamudram K, Kaiser J. Study on the impact of anemia on the Quality of Life (QoL) of cancer patients. Eur J Oncol. 2014 Feb 26;43–51.
XXIII. Buckstein R, Wells RA, Zhu NY, Geddes M, Sabloff M, Leber B, et al. Quality of Life Scores Improve with Increasing Hemoglobin but Optimal Thresholds Vary According to Transfusion Dependence and Clinical Risk Scores: A Canadian Cross Sectional Study of 689 Patients with 2969 Measurements. Blood. 2016 Dec 2;128(22):3192.
XXIV. Liu Y, Bai YP, Zhou ZF, Jiang CR, Xu Z, Fan XX. Preoperative anemia as a prognostic factor in patients with lung cancer: a systematic review and meta-analysis of epidemiological studies. J Cancer. 2019;10(9):2047–56.
XXV. Zhang YH, Lu Y, Lu H, Zhang MW, Zhou YM, Li XL, et al. Pre-treatment hemoglobin levels are an independent prognostic factor in patients with non-small cell lung cancer. Mol Clin Oncol. 2018 Jul;9(1):44–9.
XXVI. Chen C, Song Z, Wang W, Zhou J. Baseline anemia and anemia grade are independent prognostic factors for stage IV non-small cell lung cancer. Molecular and Clinical Oncology. 2021 Mar 1;14(3):1–7.
XXVII. Megasari A, Bagiada M. Ketahanan hidup 1 tahun karsinoma paru di divisi Pulmonologi RSUP Sanglah Denpasar. Medicina [Internet]. 2020 Jan 9 [cited 2023 May 11];51(1). Available from: https://www.medicinaudayana.ejournals.ca/index.php/medicina/article/view/323